Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: A pilot study

Developmental Medicine and Child Neurology

Volumn 48, Issue 9, 2006, Pages 709-712

  Plotkin, Horacio ^a,c   Coughlin, Susan ^b   Kreikemeier, Rose ^b   Heldt, Kathryn ^b   Bruzoni, Matias ^a   Lerner, Gary ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Children's Hospital Omaha   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ANTICONVULSIVE AGENT; PAMIDRONIC ACID; PARACETAMOL; PARATHYROID HORMONE;

ADOLESCENT; ARTICLE; BONE DENSITY; BONE MINERAL; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; FEMALE; FEMUR NECK; FEVER; HUMAN; HYPOCALCEMIA; IMMOBILIZATION; LOW DRUG DOSE; LUMBAR SPINE; MALE; MAXIMUM PERMISSIBLE DOSE; OSTEOPENIA; PARATHYROID HORMONE BLOOD LEVEL; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUADRIPLEGIA; SEIZURE; STATISTICAL SIGNIFICANCE;

ADOLESCENT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; DISABLED CHILDREN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRACTURES, BONE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MOBILITY LIMITATION; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33747168248     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1017/S0012162206001526     Document Type: Article

References (23)

1. Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, Jacobsson B, Damiano D. (2005) Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol 47: 571-576.
2. Rosen MG, Dickinson JC. (1992) The incidence of cerebral palsy. Am J Obstet Gynecol 167: 417-423.
3. Newacheck P, Taylor WR. (1992) Childhood chronic illness: Prevalence, severity, and impact. Am J Public Health 82: 364-371.
4. Surveillance of Cerebral Palsy in Europe. (2000) Surveillance of Cerebral Palsy in Europe: A collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol 42:816-824.
5. King W, Levin R, Schmidt R, Oestreich A, Heubi JE. (2003) Prevalence of reduced bone mass in children and adults with spastic quadriplegia. Dev Med Child Neurol 45: 12-16.
6. Crichton JU, Mackinnon M, White CP. (1995) The life-expectancy of persons with cerebral palsy. Dev Med Child Neurol 37:567-576.
7. Henderson RC, Lin PP, Greene WB. (1995) Bone-mineral density in children and adolescents who have spastic cerebral palsy. J Bone Joint Surg Am 77: 1671-1681.
8. Sholas MG, Tann B, Gaebler-Spira D. (2005) Oral bisphosphonates to treat disuse osteopenia in children with disabilities: A case series. J Pediatr Orthop 25: 326-331.
9. Henderson RC, Lark RK, Kecskemethy H, Miller F, Harcke T, Bachrach S. (2002) Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: A randomized, placebo-controlled clinical trial. J Pediat 141:644-651.
10. Rauch F, Travers R, Plotkin H, Glorieux FH. (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110: 1293-1299.
11. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. (2003) Bisphosphonate-induced osteopetrosis. N Eng J Med 349: 457-463.
12. Gandrud LM, Cheung JC, Daniels MW, Bachrach LK. (2003) Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocrinol Metab 16: 887-892.
13. Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J. (2001) Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 14: 529-533.
14. Steelman J, Zeitler P. (2003) Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr 142: 417-423.
15. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Eng J Med 339: 947-952.
16. Plotkin H, Rauch F, Bishop N, Montpetit K, Ruck-Gibbis J, Travers R, Glorieux F. (2000) Pamidronate treatment of severe osteogenesis imperfecta in children under three years of age. J Clin Endoc Metab 85: 1846-1850.
17. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. (1997) Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 39: 214-223.
18. Henderson RC, Kairalla JA, Barrington JW, Abbas A, Stevenson RD. (2005) Longitudinal changes in bone density in children and adolescents with moderate to severe cerebral palsy. J Pediatr 146: 769-775.
19. Hahn TJ, Hendin BA, Scharp CR, Boisseau VC, Haddad JGJ. (1975) Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy. N Eng J Med 292: 550-554.
20. Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH. (2003) Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinal Metab 88: 4569-4575.
21. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. (2003) Osteogenesis imperfecta types I, III and IV: Effect of pamidronate therapy on bone and mineral metabolism. J Clin Endoc Metab 88: 986-992.
22. Rosen CJ. (2003) Severe hypocalcaemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med 348: 1503-1504.
23. Peter R, Mishra V, Fraser WD. (2004) Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ 328: 335-336.